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Objectives: Intra-articularly injected monosodium iodoacetate (MIA) induces joint pathology mimicking
osteoarthritis (OA) and it is a widely used experimental model of OA. MIA induces acute inﬂammation,
cartilage degradation and joint pain. Transient Receptor Potential Ankyrin 1 (TRPA1) is an ion channel
known to mediate nociception and neurogenic inﬂammation. Here, we tested the hypothesis that TRPA1
would be involved in the development of MIA-induced acute inﬂammation, cartilage changes and joint
pain.
Methods: The effects of pharmacological blockade (by TCS 5861528) and genetic depletion of TRPA1
were studied in MIA-induced acute paw inﬂammation. Cartilage changes (histological scoring) and joint
pain (weight-bearing test) in MIA-induced experimental OA were compared between wild type and
TRPA1 deﬁcient mice. The effects of MIA were also studied in primary human OA chondrocytes and in
mouse cartilage.
Results: MIA evoked acute inﬂammation, degenerative cartilage changes and joint pain in wild type
mice. Interestingly, these responses were attenuated in TRPA1 deﬁcient animals. MIA-induced paw
inﬂammation was associated with increased tissue levels of substance P; and the inﬂammatory edema
was reduced by pretreatment with catalase, with the TRPA1 antagonist TCS 5861528 and with the
neurokinin 1 receptor antagonist L703,606. In chondrocytes, MIA enhanced interleukin-1 induced
cyclooxygenase-2 (COX-2) expression, an effect that was blunted by pharmacological inhibition and
genetic depletion of TRPA1.
Conclusions: TRPA1 was found to mediate acute inﬂammation and the development of degenerative
cartilage changes and joint pain in MIA-induced experimental OA in the mouse. The results reveal TRPA1
as a potential mediator and drug target in OA.
© 2015 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Osteoarthritis (OA) is themost common joint diseaseworldwide
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lf of Osteoarthritis Research Societis characterized by the degradation of the articular cartilage which
is associatedwith variable joint inﬂammation andmanifests in pain
and loss of joint function and eventually in the need for joint
replacement surgery.1,2
Injection of monosodium iodoacetate (MIA) into the articular
cavity induces a joint pathology mimicking that seen in human OA
and it has widely been used as an experimental model of OA3. MIA
induces a local acute inﬂammation4,5 which is followed by the
development of degenerative changes in the articular cartilage,
hyperalgesia and decreased weight-bearing on the affected limb
indicative of joint pain3,6. Similar to the situation in OA, the detailed
mechanisms related to the onset and mediation of MIA-induced
experimental OA have not been thoroughly elucidated. At they International.
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dehyde-3-phosphate dehydrogenase which induces the production
of reactive oxygen species (ROS) and caspase activation7.
Transient receptor potential ankyrin 1 (TRPA1), an ion channel
involved in nociception and neurogenic inﬂammation, has lately
attracted considerable interest as a potential drug target to treat
painful and inﬂammatory conditions8e10. In various in vivomodels,
TRPA1 activation has proven to be crucial in the triggering of in-
ﬂammatory edema11, hyperalgesia12 and pain13,14. Activation of
membrane associated TRPA1 causes an inﬂux of cations, especially
Ca2þ, which mediate the cellular responses of activation of TRPA1
such as nociception and release of proinﬂammatory neuropeptides
substance P, calcitonin gene related peptide and neurokinin A9.
TRPA1 is ligand-gated channel and its physiological role is believed
to act as a chemosensor for environmental potentially noxious
compounds such as allyl isothiocyanate (AITC) which is the pun-
gent compound present in mustard oil and widely used as a
research tool to activate TRPA110,15. In addition to environmental
irritants, many endogenously formed proinﬂammatory factors such
as hydrogen peroxide (H2O2)16, nitric oxide17 and nitro-oleic acid18
have been demonstrated to activate TRPA1.
Basedon the evidence thatMIA induces theproductionofROS and
that ROS are some of the most potent endogenous TRPA1 activators,
we postulated that TRPA1 activation could be involved in the devel-
opment of inﬂammation and inﬂammatory pain in the MIA-induced
experimental OA. Previously, two reports have been published
examining the role of TRPA1 in MIA-induced OA. In those studies, a
single doseof a TRPA1antagonist failed to alter pain-like behaviouror
to shift weight-bearing6 although the treatment was effective in
blocking mechanically induced hypersensitivity19. However, we hy-
pothesized that TRPA1 could play a role in MIA-induced acute
inﬂammation and therefore contribute to the development of MIA-
induced arthritis. In the present study, we utilized both pharmaco-
logical blockadeandgeneticdepletionofTRPA1 inorder to investigate
whether TRPA1 activation could enhance/mediate MIA-induced
acute inﬂammatory edema and cyclooxygenase-2 (COX-2) expres-
sion, and development of cartilage changes and joint pain charac-
teristic for MIA-induced experimental OA.
Materials and methods
Animals
Wild type and TRPA1 knock-out male B6; 129P-Trpa1(tm1-
Kykw)/J mice (Charles River Laboratories, Sulzfeld, Germany) were
used in the experiments investigating the effects of genetic
depletion of TRPA1. Wild type male C57BL/6N mice (Scanbur
Research A/S, Karlslunde, Denmark) were used to study the effects
of the drugs. Mice were housed under standard conditions
(12e12 h lightedark cycle, 22 ± 1C) with food and water provided
ad libitum. Animal experiments were carried out in accordance
with the legislation for the protection of animals used for scientiﬁc
purposes (Directive 2010/63/EU) and approved by the National
Animal Experiment Board. Intraperitoneal injections of medeto-
midine (0.5 mg/kg, Domitor®, Orion Oyj, Espoo, Finland) and ke-
tamine (75 mg/kg, Ketalar®, Pﬁzer Oy Animal Health, Helsinki,
Finland) were used to achieve anaesthesia. After the experiments,
the animals were sacriﬁced by carbon monoxide followed by cra-
nial dislocation. Reagents were purchased from Sigma Chemical
Co., St. Louis, MO, USA unless otherwise indicated.
Studied animal groups
Wild type mice were dosed with the selective TRPA1 antagonist
TCS 5861528 (10 mg/kg perorally), the anti-inﬂammatory steroiddexamethasone (2mg/kg intraperitoneally), the hydrogen peroxide
decomposing enzyme catalase (300 IU/paw intraplantarly), the se-
lective neurokinin 1 receptor antagonist L703,606 (10 mg/kg intra-
peritoneally, Enzo Life Sciences AG, Lausen, Switzerland) which has
been shown to block the actions of the neuropeptide substance P20
or with the vehicle (PBS intraperitoneally) prior to the experi-
ments. Orally administered drugs were diluted in 75% polyethylene
glycol and given by gavage in a volume of 250 ml 2 h prior to the
experiments. Intraperitoneally dosed drugs were diluted in PBS in a
volume of 450 ml and given 1 h prior to the experiments. Intra-
plantarly dosed drugswere diluted in PBS and given simultaneously
with the MIA. In addition, the effects of genetic depletion of TRPA1
were studied by comparing responses in TRPA1 knock-out mice and
their corresponding wild type counterparts.
Inﬂammatory paw edema test
Inﬂammatory paw edema was induced by injecting MIA
(400 mg) diluted in 50 ml of sterile 0.9% NaCl intraplantarly into the
hind paw of anesthetized mice. The contralateral paw was injected
with the vehicle and developed no measurable edema. The paw
volume was measured for up to 6 h with a plethysmometer (Ugo
Basile, Comerio, Italy) and compared to the baseline value.
Paw tissue extraction and substance P measurements
After the mice had been sacriﬁced, the inﬂamed subcutaneous
paw tissue which had been injected with MIA and the contralateral
subcutaneous paw tissue were collected for analysis into a buffer
containing Tris (50 mM, pH 7.4), NaCl (150 mM), 0.5% Triton-X and
protease and phosphatase inhibitors phenylmethylsulfonyl ﬂuoride
(0.5 mM), sodium orthovanadate (2 mM), leupeptin (0.10 mg/ml),
aprotinin (0.25 mg/ml) and NaF (1.25 mM). The tissue was minced
and incubated in the lysis buffer for 20 min with constant and
vigorous shaking. The samples were centrifuged at 10,000g for
10 min and the supernatant was collected and measured for sub-
stance P by ELISA (R&D Systems Europe Ltd., Abingdon, UK).
Spontaneous weight-bearing test
MIA-induced arthritis was triggered by injecting MIA (500 mg)
diluted in 40 ml of sterile endotoxin free PBS into the randomized
hind knee joint of an anesthetized mouse. The contralateral knee
joint was injected with the corresponding volume of the vehicle.
The willingness to bear weight on the affected joint (spontaneous
weight-bearing test) was measured with an incapacitance meter
(IITC Life Science, Woodland Hills, CA, USA) for up to 28 days and
compared to the baseline value. The mice were habituated in the
measurement room for 60 min prior to the measurement and the
subsequent measurements were carried out at the same time of the
day. In order to obtain reliable data on theweight distribution, each
mousewas measured eight times for 1 s at each time point with the
measurer blinded to the affected limb.
Histological analysis
MIA-induced OAwas induced as described above. On day 28, the
mice were sacriﬁced and the MIA and vehicle injected knee joints
were dissected and ﬁxed for 24 h in 10% formaldehyde, decalciﬁed
in Osteomoll (Merck, Darmstadt, Germany) for 48 h and embedded
in parafﬁn. Coronal sections (5 mm thick) of femoro-tibial joints
were rehydrated in a graded series of ethanol and stained with
Safranin-O-Fast-Green. The cartilage changes were scored accord-
ing to the OARSI guidelines21 by two independent observers who
were blinded to the treatment and genotype.
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Fig. 1. MIA-induced acute paw edema was inhibited by both genetic depletion and
pharmacological inhibition of TRPA1 as well as with treatment with the hydrogen
peroxide detoxifying enzyme catalase and also the neurokinin 1 receptor antagonist.
MIA induced an acute inﬂammatory edema when injected into the mouse hind paw.
Treatment with the TRPA1 antagonist, TCS 5861528 (10 mg/kg) signiﬁcantly inhibited
the MIA-induced mouse paw edema (A). Similarly, TRPA1 deﬁcient (knock-out) mice
developed an alleviated edema in response to MIA as compared to the corresponding
wild type mice (B). Furthermore, treatment with the hydrogen peroxide detoxifying
enzyme, catalase (300 IU/paw) and the neurokinin 1 receptor antagonist, L703,606
(10 mg/kg) inhibited the development of MIA-induced edema (C) similar to treatment
with the TRPA1 antagonist TCS 5861528. Administration of the glucocorticoid dexa-
methasone (2 mg/kg), used as an anti-inﬂammatory control compound, also inhibited
MIA-induced inﬂammatory edema (C). The paw volume was measured with a ple-
thysmometer before and 3 and 6 h after MIA injection (400 mg dissolved in 40 ml of
endotoxin-free phosphate buffered saline). The contralateral control paw injected with
the solvent of MIA (endotoxin-free phosphate buffered saline) developed no measur-
able edema. Paw edema is expressed as the volume change as compared to the pre-
treatment value and the results are displayed as mean þ 95% conﬁdence interval, in
A and C there were eight animals per group and in B there were six animals per group.
Data were analysed with one-way ANOVA followed by Bonferroni's multiple com-
parison test.
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chain reaction (RT-PCR) measurements
Leftover pieces of OA cartilage from knee joint replacement
surgery were used under full patient consent and approval by the
Ethics Committee of Tampere University Hospital, Tampere,
Finland. Chondrocytes were isolated and cultured as described in
the Supplementary data. The chondrocytes were incubated with
MIA (100 mM), TRPA1 antagonist HC-030031 (100 mM), IL-1b
(100 pg/ml, R&D Systems Europe Ltd.) or with combinations of
these compounds for 6 h and analyzed by RT-PCR for the expression
of COX-2 as described in the Supplementary data.
Mouse cartilage culture and Western Blotting measurements
Full-thickness articular cartilage from the femoral heads were
cultured as described in the Supplementary data. The cartilage
pieces were exposed to MIA (10 mM), TRPA1 antagonist HC-030031
(100 mM), IL-1b (100 pg/ml, R&D Systems Europe Ltd.) or to com-
binations of these agents for 24 h and the samples were analyzed
for COX-2 by Western Blotting as described in the Supplementary
data.
Ca2þ-inﬂux measurements
TRPA1 mediated Ca2þ-inﬂux was measured in HEK 293 cells22
transiently transfected with human TRPA1 as described previ-
ously11. Brieﬂy, cultured cells were loaded with ﬂuo-3-
acetoxymethyl ester (4 mM) and 0.08% Pluronic F-127® in Hanks'
balanced salt solution (HBSS) containing 1 mg/ml of bovine serum
albumin, probenecid (2.5 mM) and HEPES (25 mM, pH 7.2) for
30min at room temperature. The intracellular free Ca2þ levels were
assessed with Victor3 1420 multilabel counter (Perkin Elmer,
Waltham, MA, USA) at excitation/emission wavelengths of 485/
535 nm23. In the experiments, the cells were ﬁrst pre-incubated
with the TRPA1 antagonist HC-030031 (100 mM) or the vehicle
for 30 min at þ37C. Subsequently, MIA (100 mM) or AITC (50 mM)
was added and the measurements were continued for 30 s after
which a robust Ca2þ-inﬂux was induced by application of the
control ionophore compound, ionomycin (1 mM).
Statistical analysis
Results are expressed as mean ± 95% conﬁdence interval. Data
were analysed with SPSS 21 software (SPSS Inc, Chicago, IL, USA)
with the tests used being detailed in the ﬁgure legends.
Results
MIA induces an acute inﬂammatory response in a TRPA1 dependent
manner
Injection of MIA into the mouse paw induced an acute inﬂam-
matory edema as can be seen in Fig. 1(A)e(C). Interestingly, treat-
ment with the selective TRPA1 antagonist TCS 5861528
signiﬁcantly decreased the formation of the edema (45% and 46%
inhibition at 3 h and 6 h time points, respectively; Fig. 1(A)), sug-
gesting that the response was mediated through activation of
TRPA1. To prove the involvement of TRPA1 in the MIA-induced paw
edema, we compared the responses between TRPA1 deﬁcient and
corresponding wild type mice. In conﬁrmation of the results ob-
tained with the TRPA1 antagonist, the MIA-induced inﬂammatory
edema was signiﬁcantly reduced in TRPA1 deﬁcient mice as
compared to wild type mice, showing a 58% lower response at 3 h
and a 63% reduction at 6 h [Fig. 1(B)].
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Fig. 2. MIA induced the release of the neuropeptide substance P into the inﬂamed
paw; this effect was inhibited by both genetic depletion and pharmacological inhibi-
tion of TRPA1 but not by treatment with the neurokinin 1 receptor antagonist. Sub-
stance P concentrations were elevated in the mouse paw following an injection of MIA.
Interestingly, substance P release was lower in TRPA1 deﬁcient (knock-out) mice as
compared to the corresponding wild type mice (A). Similarly, treatment with the
TRPA1 antagonist TCS 5861528 (10 mg/kg) inhibited the release of substance P
whereas the neurokinin 1 receptor antagonist L703,606 (10 mg/kg) had a negligible
effect (B). The affected paw of the studied mice was injected with MIA (400 mg dis-
solved in 40 ml of endotoxin-free phosphate buffered saline) whereas the contralateral
control paw was injected with the solvent (endotoxin-free phosphate buffered saline).
After 6 h, the mice were sacriﬁced and the collected paw tissue samples were analysed
for substance P concentrations by ELISA. The results are displayed as mean þ 95%
conﬁdence interval, in (A) there were six animals per group and in (B) eight animals
per group. Data were analysed with one-way ANOVA followed by Bonferroni's multiple
comparison test.
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tory edema were ﬁrst examined by treating the animals with the
hydrogen peroxide degrading enzyme catalase. Based on the fact
that MIA induces production of ROS7 which also are known to
activate TRPA110,16, we hypothesized that the generation of
hydrogen peroxide could mediate the inﬂammatory reaction
induced by the injection of MIA. Interestingly, catalase caused a
clear decrease in MIA-induced paw edema (48% and 49% inhibition
at 3 h and 6 h time points, respectively) as seen in Fig. 1(C).
The inﬂammatory effects of TRPA1 activation are frequently
explained by the release of neuropeptides, especially substance P,
and the promotion of neurogenic inﬂammation9,10. Therefore, we
investigated the effects of the blockade of the receptor for sub-
stance P by using the neurokinin 1 receptor antagonist L703,60620.
As seen in Fig. 1(C), treatment with L703,606 inhibited the MIA-
induced paw edema by 42% at 3 h and by 36% at 6 h time points.
Furthermore, MIA induced an increase in substance P levels in the
inﬂamed paw tissue as shown in Fig. 2(A)e(B) and this increasewas
attenuated in TRPA1 knock-out mice [Fig. 2(A)]. Accordingly, pre-
treatment with the TRPA1 antagonist TCS 5861528 reduced the
MIA-induced increase in substance P levels whereas L703,606 had
no effect, as expected [Fig. 2(B)].
MIA induces COX-2 expression in chondrocytes in a TRPA1
dependent manner
Activation of TRPA1 has been reported to enhance the expres-
sion of the inducible prostaglandin synthase, COX-2, in some cell
types11. MIA has also been found to increase COX-2 expression in
OA joints24,25. Therefore we decided to investigate whether the
pattern described above (i.e., that TRPA1mediates theMIA-induced
acute inﬂammatory edema) could also be extended toMIA-induced
responses in human chondrocytes, focusing on COX-2 expression.
We cultured primary chondrocytes derived from patients with
OA and used RT-PCR to conﬁrm that TRPA1 was expressed in these
cells. Next, we treated the chondrocytes with MIA, the selective
TRPA1 antagonist HC-030031 or their combination with and
without interleukin-1b (IL-1b) stimulation. MIA or HC-030031
alone did not alter COX-2 expression. Nonetheless, MIA clearly
increased COX-2 expression in IL-1b stimulated chondrocytes.
Furthermore, treatment with the TRPA1 antagonist HC-030031
abolished the MIA-induced increase in COX-2 expression as
shown in Fig. 3(A).
The ﬁnding described above suggests that MIA can induce COX-
2 expression in OA chondrocytes in a TRPA1-mediated manner. The
mediator role of TRPA1 in that process was elucidated by deter-
mining COX-2 expression in articular cartilage from wild type and
TRPA1 deﬁcient mice. In support of the ﬁndings obtained in pri-
mary human OA chondrocytes, MIA increased COX-2 expression in
IL-1b-stimulated cartilage from wild type [Fig. 3(B)] but not from
TRPA1 knock-out [Fig. 3(C)] mice, and furthermore in the wild type
mice, the effect of MIA was inhibited by the TRPA1 antagonist HC-
030031 [Fig. 3(B)].
Attenuation of MIA-induced joint pain and cartilage changes in
TRPA1 deﬁcient mice
As a consequence of the acute inﬂammation, the development
of cartilage degradation and joint pain are characteristic features
encountered in MIA-induced OA. The latter is usually measured by
an incapacitance meter in the so-called weight-bearing test3,6. As
TRPA1 has been reported to mediate various forms of neuropathic
and inﬂammatory pain9,10, we investigated whether TRPA1 was
also involved in the development of the MIA-induced joint pain.
When MIA was injected into one knee joint, wild type micedeveloped a reduction in spontaneous weight-bearing on the
affected joint, indicative of joint pain. Interestingly, an attenuated
response was detected in TRPA1 deﬁcient mice as seen in
Fig. 4(A)e(B), suggesting that TRPA1 is indeed involved in the
development of the joint pain typical of MIA-induced OA.
Furthermore, the score of MIA-induced histological changes in the
cartilage according to the OARSI guidelines21 was lower in TRPA1
deﬁcient than in wild type mice (Fig. 5).MIA is not a direct activator of TRPA1 ion channels
As many of the MIA-induced responses were found to be
mediated through TRPA1, we asked the question if MIA could be a
direct activator of TRPA1 ion channels. To investigate that possi-
bility, MIAwas introduced to HEK 293 cells transfected with TRPA1.
MIA did not induce Ca2þ-inﬂux into the studied cells whereas the
known TRPA1 agonist AITC induced an intense Ca2þ-inﬂux which
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Fig. 3. MIA-induced COX-2 expression was reduced by pharmacological inhibition and genetic depletion of TRPA1. In primary cultures of human osteoarthritic chondrocytes,
treatment with the TRPA1 antagonist HC-030031 reduced the expression of the proinﬂammatory gene COX-2 induced by co-stimulation with MIA and IL-1b (A). Correspondingly in
the cartilage derived from mice, MIA increased COX-2 expression in IL-1b stimulated cartilage fromwild type but not from TRPA1 deﬁcient (knock-out) mice (B). The samples were
cultured with the studied compounds for 6 h and analyzed for COX-2 mRNA expression by RT-PCR (A) or for 24 h and analyzed for COX-2 protein expression byWestern Blotting (B).
The mRNA expression was normalized against housekeeping gene GAPDH (A) and the protein expression against loading control actin (B). The response in IL-1b treated chon-
drocytes/cartilage was set at 100% and the other results were calculated in relation to that value. The results are displayed as mean þ 95% conﬁdence interval. The human samples
were obtained from six different donors and the experiments were performed in triplicate (A). The cartilage samples were from ﬁve mouse (n ¼ 5) in each treatment (B and C). Data
were analysed with SPSS software with one-way ANOVA followed by Bonferroni's multiple comparison test.
L.J. Moilanen et al. / Osteoarthritis and Cartilage 23 (2015) 2017e2026 2021could be inhibited by treatment with the TRPA1 antagonist HC-
030031 as seen in Fig. 6. These data indicate that MIA is not a
direct TRPA1 agonist but most likely induces a release of endoge-
nous TRPA1 activators which are responsible for the TRPA1-
mediated effects of MIA discovered in the present study.
Discussion
The present study revealed that MIA-induced acute inﬂamma-
tion was reduced in TRPA1 deﬁcient mice as well as by the treat-
ment with the TRPA1 antagonist TCS 5861528, the neurokinin 1
receptor antagonist L703,606 and the H2O2 degrading enzyme
catalase. We also demonstrated that the spontaneous weight shiftaway from theMIA-injected limbwas attenuated in TRPA1 deﬁcient
mice when compared to the corresponding wild type mice.
Furthermore, MIA-induced cartilage changes were less severe in
TRPA1 deﬁcientmice. These results together suggest that the TRPA1
ion channel is signiﬁcantly involved in the development of MIA-
induced acute inﬂammation, cartilage changes and joint pain.
Originally TRPA1 was described in fetal lung ﬁbroblasts in
199926. Thereafter it has been shown that TRPA1 is expressed in
different afferent sensory neurons such as Ad- and C-ﬁbers27.
Moreover, substantial non-neuronal expression and function of
TRPA1 have been identiﬁed in lining cells such as keratinocytes,
synoviocytes and endothelial cells10,28. The physiological role of
TRPA1 is believed to be in the sensing of exogenous irritating and
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Fig. 4. TRPA1 deﬁcient mice exhibited an attenuated response to MIA in the weight-
bearing test indicative of alleviated joint pain. When MIA was injected into one knee
joint, wild type mice exhibited a reduction in spontaneous weight-bearing on the
affected limb indicative of joint pain. Interestingly, an attenuated weight distribution
change was seen in TRPA1 deﬁcient (knock-out) mice. Spontaneous distribution of
weight between the hind limbs was measured with an incapacitance meter before and
at 7, 14 and 28 days after intra-articular injection of MIA (500 mg dissolved in 40 ml of
endotoxin free phosphate buffered saline). The contralateral knee joint was injected
with the solvent of MIA (endotoxin-free phosphate buffered saline) and the measurer
was blinded for the affected limb. In (A), results are displayed as difference of per-
centage points between the weight bore by the affected and non-affected limb and
given as mean þ 95% conﬁdence interval, n ¼ 7 animals in wild type and TRPA1
deﬁcient groups. Data were analysed by using mixed between-within subjects ANOVA
and a statistically signiﬁcant difference between the two genotypes was found
(P ¼ 0.045). In (B), the area-under-the curve (AUC) for the shift from the equal balance
between the hind limbs was calculated, and the results of wild type and TRPA1 deﬁ-
cient mice are presented as mean þ 95% conﬁdence interval, n ¼ 7 animals in wild type
and TRPA1 deﬁcient groups. Data were analysed by using unpaired T-test and a sta-
tistically signiﬁcant difference between the two genotypes was found (P ¼ 0.041).
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TRPA1 possesses also the ability to promote inﬂammation9,10.
TRPA1 has been proven to be crucial for the development of in-
ﬂammatory edema11, hyperalgesia12 and pain13,14 in pathological
conditions such as airway hyperreactivity and inﬂammation29,30,
acute gouty arthritis31 and neurogenic inﬂammation associatedwith colitis32. In addition to the fact that TRPA1 is activated by
endogenously formed reactive oxygen and nitrogen species and
their metabolites16, TRPA1 is also sensitized by several secondary
messengers, i.e., phospholipase C and protein kinase A33, which are
activated by various proinﬂammatory mediators through their G-
protein coupled receptors. Activation of TRPA1 primarily leads to
pain sensation and ampliﬁcation of neurogenic inﬂammation by
promoting the release of neuropeptides such as substance P and
calcitonin-gene related peptide9,10. In addition, many other sec-
ondary inﬂammatory mechanisms following TRPA1 activation have
been identiﬁed. For example, inﬂammatory edema caused by
TRPA1 activation is mediated through mechanisms such as mast
cell degranulation, neutrophil migration, the release of histamine,
serotonin and adrenaline as well as the production of prostaglan-
dins11,34. In addition, the activation of TRPA1 has been shown to
enhance the expression of inﬂammatory genes such as prosta-
glandin producing enzyme COX-2, myeloperoxidase and IL-
1b11,35e37.
An injection of MIA into a rodent's knee joint is a widely used
experimental model to study OA as it triggers the changes resem-
bling the histological and pathophysiological features of the human
disease38e41. In addition, pain-like behavior appears within a few
weeks; this is commonly evaluated by the weight-bearing
test38,39,41. The mechanism of action of MIA has been attributed
to inhibition of glyceraldehyde-3-phosphate dehydrogenase. This
disrupts the glucose metabolism of chondrocytes, leading to ROS
production and caspase activation, and further to the catabolism of
cartilage matrix and cell death which can be detected both in vivo
and in vitro7,38,42,43. In addition to evoking cartilage degradation,
MIA induces an acute inﬂammation which is associated with
edema formation and increased expression of proinﬂammatory
factors such as IL-1b, IL-6, IL-15, inducible nitric oxide synthase
(iNOS), COX-2 andmetalloproteinase-1324,25. Interestingly, MIA has
also been demonstrated to trigger an early release of neuropep-
tides, substance P and calcitonin gene related peptide44.
Even though the role of TRPA1 in MIA-induced inﬂammation
and cartilage changes has previously been unknown, there are two
studies which have investigated TRPA1 in MIA-induced OA,
although focusing on pain. Curiously, a single dose of TRPA1
antagonist given shortly prior to the measurements failed to alter
pain-like behaviour or cause any change in weight-bearing test at
the later stage of the arthritis6 but it was effective in blocking
mechanically induced hypersensitivity19. However, these studies
focused mainly on noxious neuronal signals and pain mediated by
activation of TRPA1, but they did not examine acute inﬂammation
or the long-term effect of TRPA1 on the development of the joint
pain or cartilage changes induced by MIA. In the current study, we
were able to link the activation of TRPA1 to the formation of MIA-
induced acute inﬂammation and cartilage changes and we also
observed a diminished weight shift in TRPA1 knock-out mice
reﬂecting an alleviation of joint pain.
The present results demonstrate that the MIA-induced acute
inﬂammatory paw edema was dependent on TRPA1 activation.
Both genetic depletion and pharmacological inhibition of TRPA1
were highly effective in reducing the edema. Furthermore, the
extent of the edema was also reduced by treatment with the
hydrogen peroxide detoxifying enzyme catalase indicating that the
edema was likely attributable to hydrogen peroxide. The edema
formation was also reversed by treatment with L703,606, a com-
pound which antagonises the neurokinin 1 receptor known to be
the main receptor for substance P. Importantly, when the concen-
trations of substance P were assayed in the inﬂamed paw tissue,
they were found to be diminished in the TRPA1 knock-out mice as
compared to the wild type mice as well as in mice treated with the
TRPA1 antagonist TCS 5861528, but as expected, treatment with
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Fig. 5. TRPA1 deﬁcient mice developed less severe cartilage changes in the knee joint following MIA injection. When MIAwas injected into the knee joint, wild type mice developed
more severe cartilage changes than TRPA1 deﬁcient (knock-out) mice. Twenty-eight days after intra-articular injection of MIA (500 mg dissolved in 40 ml of endotoxin-free
phosphate buffered saline) in one knee joint and the solvent of MIA (endotoxin-free phosphate buffered saline) in the contralateral joint, mice were sacriﬁced and the knee
joints were dissected for histology. The cartilage changes were scored according to the OARSI guidelines. In (A), the whole joint histopathological score is presented. The results are
displayed as mean þ 95% conﬁdence interval, n ¼ 7 animals in wild type and TRPA1 deﬁcient groups. Data were analysed with SPSS software by using one-way ANOVA with
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L.J. Moilanen et al. / Osteoarthritis and Cartilage 23 (2015) 2017e2026 2023L703,606 did not alter the levels of substance P. Based on the pre-
sent results, the likely sequence of events is that ﬁrst MIA induces
the formation of ROS in the target cells; second, the ROS activate
TRPA1 leading to release of substance P; and third, the released
substance P activates the neurokinin 1 receptor to induce the acute
inﬂammatory response. Within a few weeks after the intra-
articular injection of MIA, one can see evidence of degenerating
cartilage and joint pain and both of those responses appear to be
alleviated in TRPA1 deﬁcient mice. Based on the present data, it is
tempting to propose causality between the MIA-induced acute
inﬂammation and the subsequent OA-like changes, but further
studies will be needed to reveal their association.
Even though classically the function of TRPA1 has mainly been
studied in sensory nerves, non-neuronal expression and function ofTRPA1 are now clearly recognized28. In the present study, we
observed the expression of TRPA1 in human primary chondrocytes
derived from OA patients. In view of the known effects of MIA on
chondrocytes25, we decided to study the possible effects of TRPA1
in cultured human chondrocytes. When the cells were stimulated
with MIA and IL-1b, the expression of the proinﬂammatory gene
COX-2 was increased and this could be inhibited by treatment with
the TRPA1 antagonist HC-030031. The results were in parallel with
ﬁndings in cultured murine cartilage; MIA induced a clear increase
in COX-2 expression in IL-1b-stimulated cartilage from wild type
mice but this effect was not seen in cartilage from TRPA1 deﬁcient
mice. These results were comparable to those obtained earlier in
TRPA1 transfected HEK 293 cells11 indicating that the proin-
ﬂammatory properties of TRPA1 might not be exclusively due to its
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treatment with the selective TRPA1 antagonist HC-030031 (C). HEK 293 cells were
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the Methods. The intracellular Ca2þ concentration was measured by Victor3 multilabel
counter at excitation/emission wavelengths of 485/535 nm at 1/s frequency. The cells
were ﬁrst pre-incubated with HC-030031 (100 mM) (C) or the vehicle (AeB) for 30 min
at þ37C. In the experiments (AeC), basal ﬂuorescence was ﬁrst measured for 15 s and
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owing), n ¼ 6.
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explaining how TRPA1 activation results in increased COX-2
expression but intracellular Ca2þ levels may be the link. TRPA1
activation elevates the intracellular Ca2þ concentration which may
have either a direct or an indirect effect on the expression of in-
ﬂammatory genes including COX-2 as reported previously45e47. It is
noteworthy however, that substance P is expressed in chondrocytes
and this neuropeptide modulates their functions48 and therefore
the effects seen could also be due to autocrine signalling.
When we scaled up the study setting and analysed the MIA-
induced joint pain with the weight-bearing test, we found that
the pain response was attenuated in TRPA1 deﬁcient mice. The
MIA-induced weight-bearing test is often performed in rats since
these animals display a larger change in weight distribution be-
tween their lower limbs than mice and this should be considered
when interpreting the present results. Despite this limitation, the
use of mice was justiﬁed in the current study because the mouse is
the only available TRPA1 deﬁcient species. The weight distribution
change reported here in wild type mice was of a similar magnitude
as reported previously with this model49. Although the pathogen-
esis of the MIA-induced joint pain is not fully understood, it could
be initiated and then modiﬁed by the early inﬂammation induced
by MIA3,49 and the present results clearly show a diminished acute
inﬂammation in response to MIA in TRPA1 deﬁcient mice. Arthritis
involves many cell types including neurons, chondrocytes and
synoviocytes all of which express TRPA1 and its activation may
trigger or regulate the pathogenesis of arthritis. Interestingly,
neuropeptides are known to be involved in arthritis50 and for
example the expression of the receptor for substance P, i.e., the
neurokinin 1 receptor, is abundant48. Therefore it is clearly possible
that activation of TRPA1 resulting in the release of neuropeptides
such as substance P plays a role in the pathogenesis of OA.
At the moment, the therapy of OA is based on analgesic drugs,
physical exercise, reduction of overweight and ultimately joint
replacement surgery. Unfortunately, no effective disease modifying
drugs are available. The present study introduces TRPA1 as a factor
involved in mediating the acute inﬂammation and development ofcartilage changes and joint pain in MIA-induced experimental OA.
As the experimental model mimics many of the features of human
OA, the present results raise the possibility that TRPA1 may play a
central role also in the pathogenesis of OA and thus provide a novel
target for analgesic and anti-inﬂammatory drugs with disease
modifying potential.
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